INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Inovio Pharma (INO) Tops Q4 EPS by 8c
March 1, 2021 4:19 PM ESTInovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.14), $0.08 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $5.6 million versus the consensus estimate of $1.11 million.
Dr. J. Joseph Kim, INOVIO\'s President and CEO, said, "We have had a productive fourth quarter across our DNA medicines platform, including... More
